- Previous Close
0.4080 - Open
0.4080 - Bid 0.3960 x 3669800
- Ask 0.4640 x 3183100
- Day's Range
0.4080 - 0.4080 - 52 Week Range
0.2360 - 0.4920 - Volume
417 - Avg. Volume
1,098 - Market Cap (intraday)
288.237M - Beta (5Y Monthly) 0.62
- PE Ratio (TTM)
3.71 - EPS (TTM)
0.1100 - Earnings Date Jan 28, 2025 - Feb 3, 2025
- Forward Dividend & Yield 0.03 (8.36%)
- Ex-Dividend Date Nov 22, 2024
- 1y Target Est
--
Beximco Pharmaceuticals Limited manufactures and markets generic pharmaceutical formulations and active pharmaceutical ingredients in Bangladesh. The company provides allergic disorder, analgesics and antipyretic, anti-infective, antiviral, cardiovascular, central nervous system, cough and cold, endocrine and diabetes, eye care, gastrointestinal, hormone and steroid, intravenous fluid, musculoskeletal, oncology, respiratory, urogenital, skin care, vitamin and mineral supplement, and other products, as well as contract manufacturing services to other companies. It offers its products in various dosage forms, including solid, liquid, cream and ointment, suppositories, metered dose and dry powder inhaler, nasal spray, sterile, lyophilized injectable, and large volume intravenous fluids. The company also exports its products. Beximco Pharmaceuticals Limited was incorporated in 1976 and is headquartered in Dhaka, Bangladesh.
www.beximcopharma.com1,122
Full Time Employees
June 30
Fiscal Year Ends
Sector
Recent News: R2WA.F
View MorePerformance Overview: R2WA.F
Trailing total returns as of 12/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: R2WA.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: R2WA.F
View MoreValuation Measures
Market Cap
287.98M
Enterprise Value
316.66M
Trailing P/E
3.85
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.51
Price/Book (mrq)
0.46
Enterprise Value/Revenue
0.89
Enterprise Value/EBITDA
4.56
Financial Highlights
Profitability and Income Statement
Profit Margin
13.13%
Return on Assets (ttm)
7.48%
Return on Equity (ttm)
11.79%
Revenue (ttm)
44.39B
Net Income Avi to Common (ttm)
5.83B
Diluted EPS (ttm)
0.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
1.22B
Total Debt/Equity (mrq)
11.61%
Levered Free Cash Flow (ttm)
4.13B